1. Neuroprotective effects of Tradescantia spathacea tea bioactives in Parkinson’s disease: In vivo proof-of-concept
- Author
-
Lorenna E.S. Lopes, Sheilla da Silva Barroso, Joanny K.M. Caldas, Paulo R. Vasconcelos, Kirley M. Canuto, Claudio Dariva, Klebson S. Santos, Patricia Severino, Juliana C. Cardoso, Eliana B. Souto, and Margarete Z. Gomes
- Subjects
Neuroprotective agents ,Parkinson’s disease ,Preclinical evaluation ,Infusion ,Tradescantia ,Medicine - Abstract
Background and aim: Tradescantia spathacea (T. spathacea) is a traditional medicinal plant from Central America and its tea, obtained by infusion, has been recognized as a functional food. The aim of this work was to investigate the effects of dry tea containing biocompounds from T. spathacea tea on motor and emotional behavior, as well as tyrosine hydroxylase (TH) and glial fibrillary acidic protein (GFAP) expression in 6-hydroxydopamine (6-OHDA)-lesioned rats. Experimental procedure: Bioactives were identified by Ultra Performance Liquid Chromatography (UPLC) and an in vivo study in male Wistar rats was run as proof of concept of neuroprotective effects of DTTS. Results and conclusion: We found 15 biocompounds that had not been previously reported in T. spathacea: the UPLC-QTOF-MS/MS allowed identification five phenolic acids, one coumarin, two flavonoids, one iridoid, one phenylpropanoid glycoside, and six fatty acid derivatives. The dry tea of T. spathacea (DTTS) presented significant antioxidant activity and high contents of phenolic compounds and flavonoids. Doses of 10, 30, and 100 mg/kg of DTTS were protective against dopaminergic neurodegeneration and exhibited modulatory action on the astrocyte-mediated neuroinflammatory response. Behavioral tests showed that 30 mg/kg of DTTS counteracted motor impairment, while 100 mg/kg produced an anxiolytic effect. The DTTS could be, therefore, a promising strategy for the management of Parkinson's disease.
- Published
- 2024
- Full Text
- View/download PDF